TICKERNERD
Menu
DCOYHealthcare · Biotechnology

DCOY Stock Forecast: Decoy Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Aug 2026
$3.28
−3.81% on the day

The 1 Wall Street analysts covering Decoy Therapeutics, Inc. hold a median 12-month price target of $30 — +814.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.1M
Ticker Nerd rank
12 / 100
Median analyst target
$30
Analysts covering
1
Total return, dividends reinvested
1W
−7.1%
1M
−38.2%
YTD
−57.9%
1Y
−95.0%
From 52W high
−95.4%
From 52W low
0.0%
$3
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DCOY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Decoy Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
99
Accruals
59
Growth
26
Revisions
25
Issuance
22
Volatility
22
Momentum
19
Quality
17
Value
4

Size (99): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DCOY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DCOY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26DCOYHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +814.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Jan 2026Ladenburg ThalmannInitiatesBuy$2.50
11 Mar 2022HC Wainwright & Co.MaintainsBuy$5.00 → $4.00
25 Aug 2021HC Wainwright & Co.InitiatesBuy—
16 June 2020BenchmarkInitiatesSpeculative Buy—
27 Apr 2020Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DCOY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

DCOY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Decoy Therapeutics, Inc. (DCOY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 74% of US stocks

Price / sales
9.2×

Cheaper than 15% of US stocks

Price / book
0.3×

Cheaper than 88% of US stocks

EV / EBITDA
1.0×

Cheaper than 57% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−1055.8%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−827.8%

Higher than 2% of US stocks

Return on assets
−73.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

DCOY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DCOYDecoy Therapeutics, Inc.$2.1M
12
SLXNSilexion Therapeutics Corp.$2.2M
53
CDTCDT Equity, Inc.$2.3M
15
OGENOragenics, Inc.$2.3M
10
VRAXVirax Biolabs Group Ltd.$2.5M
13
BBLGBone Biologics Corp.$1.7M
23
ONCOOnconetix, Inc.$2.6M
14

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Decoy Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DCOY news & analysis

Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform

PRNewsWire · 3 Aug 2026positive

Decoy Therapeutics announced the expansion of its intellectual property portfolio, which now spans seven patent families and 19 pending applications across seven jurisdictions. The portfolio covers antiviral peptide conjugates, methods of manufacture, formulations, and the company's IMP³ACT design platform for its Designable Multi-Antivirals.

Why it matters — A broader and more extensive IP portfolio could strengthen Decoy's protection of its D-MAV platform and pipeline assets.

Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats

PRNewsWire · 27 July 2026positive

Decoy Therapeutics announced that one of its D-MAV candidates demonstrated in vitro activity against wild-type Ebola Zaire virus in testing at the Texas Biomedical Research Institute, validating its D-MAV platform and expanding into filovirus pandemic preparedness.

Why it matters — A DCOY watcher would care because this news validates the D-MAV platform's cross-viral family fusion inhibition capability and opens a new program addressing high-consequence global health threats.

FAQ

Frequently asked questions about DCOY stock

What is the DCOY stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Decoy Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DCOY stock a buy right now?

Of the 1 analysts covering Decoy Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Decoy Therapeutics, Inc. 12 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DCOY?

As at 22 Aug 2026, Decoy Therapeutics, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).

Will DCOY stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +814.6% from the last close, and Ticker Nerd's factor model ranks Decoy Therapeutics, Inc. 12 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DCOY stock forecast for 2030?

No analyst covering Decoy Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DCOY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has DCOY stock performed over the past year?

Decoy Therapeutics, Inc. returned -95.0% over the 12 months to 20 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Decoy Therapeutics, Inc. do?

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer who have limited treatment options.

What is the latest news on DCOY?

The most recent item we track (PRNewsWire, 3 Aug 2026): "Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform". Decoy Therapeutics announced the expansion of its intellectual property portfolio, which now spans seven patent families and 19 pending applications across seven jurisdictions. The portfolio covers antiviral peptide conjugates, methods of manufacture, formulations, and the company's IMP³ACT design platform for its Designable Multi-Antivirals.

Company

About Decoy Therapeutics, Inc.

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer who have limited treatment options. The company’s primary activity centers on discovering and advancing novel small-molecule and peptide-based drug candidates targeting difficult-to-treat malignancies. Its portfolio includes investigational therapies designed to modulate epigenetic and protein-degradation pathways, aiming to address hematologic cancers and solid tumors where existing treatments are inadequate. Salarius Pharmaceuticals operates today in the context of its combination with Decoy Therapeutics, whose AI- and machine learning–enabled platform is used to design and engineer next-generation peptide-conjugate drug candidates. This platform is applied to areas of high unmet medical need, including respiratory viral diseases and gastrointestinal cancers. Headquartered in Houston, Texas, with related research activities connected to hubs such as Cambridge, Massachusetts and New York, the company participates in the broader oncology and antiviral drug development ecosystem, working alongside academic centers, clinical investigators, and industry partners to move its pipeline through preclinical and early clinical development.

CEO Mr. Frederick E. Pierce II · 11 employees · United States · https://decoytx.com